Imago BioSciences is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for hematologic disorders by targeting epigenetic enzymes, principally LSD1. Its lead candidate, bomedemstat (IMG-7289), is an orally available small-molecule LSD1 inhibitor being evaluated in Phase 2b trials for myelofibrosis and essential thrombocythemia and is also being studied in other myeloid malignancy trials. The FDA has granted bomedemstat Fast Track and Orphan Drug Designations for myelofibrosis and essential thrombocythemia, and the EMA has given PRIME designation for myelofibrosis. Imago will use the proceeds from the financing to complete a Phase 3 study of bomedemstat for myeloproliferative neoplasms. The company is based in South San Francisco, California. Imago BioSciences is a clinical-stage, venture-backed pharmaceutical company focused on proliferative diseases of the bone marrow and immune modulation. Its lead program is IMG-7289, a small molecule LSD1 (KDM1A) inhibitor with demonstrated anti-tumor efficacy in non-clinical models and activity in combination with other agents. Imago completed a Phase 1/2a study of IMG-7289 in late 2018 and has initiated a global Phase 2b study in patients with myelofibrosis; additional indications are planned. The company intends to advance research and clinical development programs for myelofibrosis and other myeloid neoplasms. Imago is based in California and will use proceeds from its recent financing to fund these clinical programs. Imago BioSciences is a San Francisco–based clinical development company focused on therapeutics that alter gene expression patterns. It is dedicated to orphan diseases involving genetic alterations that disturb normal gene expression, and to conditions where modifying gene expression could have a therapeutic effect. The company is led by CEO Hugh Young Rienhoff, M.D. Proceeds from the recent financing will be used to advance its research and clinical development programs for these therapeutics. Imago raised $26.5M in a Series A to fund those programs. The round included participation from strategic life-science investors to support its clinical efforts.

Total raised

$147M

Funding rounds

3

Latest round

Series C

Latest activity

Nov 2020